CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 199 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2015. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2015 | $1,892,000 | -32.1% | 75,000 | -25.0% | 0.60% | -49.1% |
| Q1 2015 | $2,787,000 | +52.7% | 100,000 | 0.0% | 1.17% | +32.9% |
| Q4 2014 | $1,825,000 | -6.1% | 100,000 | -33.3% | 0.88% | -15.0% |
| Q3 2014 | $1,944,000 | -43.3% | 150,000 | -28.6% | 1.04% | -35.1% |
| Q2 2014 | $3,427,000 | -9.8% | 210,000 | -2.3% | 1.60% | -8.9% |
| Q1 2014 | $3,799,000 | -21.5% | 215,000 | +7.5% | 1.76% | -36.4% |
| Q4 2013 | $4,842,000 | – | 200,000 | – | 2.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| KLP Enterprises, LLC | 6,865,000 | $3,096,000 | 100.00% |
| TSP Capital Management Group, LLC | 698,674 | $1,549,000 | 0.79% |
| Meditor Group Ltd | 6,312,700 | $2,847,000 | 0.61% |
| Telemetry Investments, L.L.C. | 186,200 | $84,000 | 0.04% |
| GSA CAPITAL PARTNERS LLP | 1,270,500 | $573,000 | 0.03% |
| Benchmark Capital Advisors | 53,400 | $24,000 | 0.02% |
| BOENNING & SCATTERGOOD, INC. | 80,150 | $36,000 | 0.01% |
| NJ State Employees Deferred Compensation Plan | 80,000 | $36,000 | 0.01% |
| Centiva Capital, LP | 121,720 | $55,000 | 0.01% |
| Overbrook Management Corp | 48,611 | $22,000 | 0.00% |